Novocure (NASDAQ: NVCR) — Company Overview, News & Financial Data
Novocure develops innovative therapies using Tumor Treating Fields technology to treat various types of cancer.
Novocure
Novocure (NASDAQ:NVCR) is a global oncology company dedicated to developing a novel platform technology, Tumor Treating Fields, to create therapies for various types of cancer. This technology uses electric fields to disrupt cancer cell division, potentially improving survival for patients. Novocure's operations span research, clinical development, and the commercialization of its products worldwide, aiming to transform cancer treatment through its innovative approach. Its flagship project involves the treatment of glioblastoma, a type of brain cancer, but the company is also exploring applications in other solid tumor cancers. Novocure's objectives focus on expanding the understanding and efficacy of Tumor Treating Fields, investing in clinical trials to explore new indications, and enhancing patient access to its treatments.
Snapshot
Operations
Products and/or services of Novocure
- Optune, a wearable medical device for the treatment of adult patients with glioblastoma multiforme.
- Optune Lua, designed for the treatment of malignant pleural mesothelioma.
- Tumor Treating Fields (TTFields) technology, utilizing electric fields to disrupt cancer cell division and inhibit tumor growth.
- Research in pancreatic cancer, exploring the use of TTFields to treat this type of cancer.
- Clinical trials for non-small cell lung cancer (NSCLC), investigating TTFields in combination with standard therapies.
- Development of innovative TTFields delivery systems, aimed at improving patient comfort and treatment adherence.
Novocure executive team
- William F. DoyleExecutive Chairman
- Frank LeonardCEO & Director
- Christoph BrackmannChief Financial Officer
- Michael PuriChief Human Resources Officer
- Uri WeinbergChief Innovation Officer & Chief Medical Officer
- Mukund ParavasthuChief Operating Officer
- Adam DaneyHead of Investor Relations
- Barak Ben-AryeGeneral Counsel
Key financials
Reported results for Novocure, in USD.
- Market cap
- 1.5B
- Revenue (TTM)
- 725.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.1
- Dividend yield
- —
- Profit margin
- -16.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 655.4M | -153.8M | -136.2M | |
| 605.2M | -170.5M | -168.6M | |
| 509.3M | -232.9M | -207M | |
| 537.8M | -89.5M | -92.5M |